Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.97
Xeris Biopharma Holdings, Inc. incurred convertible notes of $33,574,000 with qualified institutional buyers at 8.00% per annum maturing July 15, 2028.
- Instrument
- convertible notes
- Principal
- $33,574,000
- Counterparty
- qualified institutional buyers
- Rate
- 8.00% per annum
- Maturity
- July 15, 2028
- Event
- incurrence
Exact text from the filing
Xeris Biopharma Holdings, Inc., a Delaware corporation (the “ Company ”), and Xeris Pharmaceuticals, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (the “ Guarantor ”), closed the previously announced exchange of $31,975,000 in aggregate principal amount of the Guarantor’s 5.00% Convertible Senior Notes due 2025 (the “ Existing Notes ”) for $33,574,000 in aggregate principal amount of the Company’s new 8.00% Convertible Senior Notes due 2028 (the “ New Notes ”) (the “ Exchange Transactions ”)
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Xeris Biopharma Holdings, Inc. entered into Indenture for 8.00% Convertible Senior Notes due 2028 with U.S. Bank Trust Company, National Association valued at $33,574,000 in aggregate principal amount of 8.00% Convertible Senior Notes due 2028 (effective 2023-09-29).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- U.S. Bank Trust Company, National Association
- Value
- $33,574,000 in aggregate principal amount of 8.00% Convertible Senior Notes due 2028
- Effective
- 2023-09-29
Exact text from the filing
On September 29, 2023, Xeris Biopharma Holdings, Inc., a Delaware corporation (the " Company "), and Xeris Pharmaceuticals, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (the " Guarantor "), closed the previously announced exchange of $31,975,000 in aggregate principal amount of the Guarantor’s 5.00% Convertible Senior Notes due 2025 (the " Existing Notes ") for $33,574,000 in aggregate principal amount of the Company’s new 8.00% Convertible Senior Notes due 2028 (the " New Notes ") (the " Exchange Transactions "), in each case, pursuant to the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended (the " Securities Act ").
View on SEC.gov